Twitter Facebook LinkedIn YouTube

Ortho Regenerative Technologies (CSE:ORTH) New Listing

Video Platform Video Management Video Solutions Video Player

Quebec-based Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair technology to dramatically improve the success rate of sports medicine surgeries for soft tissue injuries.

Additional Information:

Company: Ortho Regenerative Technologies
Website: http://www.orthorti.com
Stock Symbol: CSE: ORTH
Date Published: Oct 11, 2017
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for Investmentpitch Media

Ortho Regenerative Technologies is the latest new listing on the Canadian Securities Exchange, trading under the symbol “ORTH”.

Quebec-based Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair technology to dramatically improve the success rate of sports medicine surgeries for soft tissue injuries.

The company’s proprietary biopolymer has been specifically designed to increase the healing rates of injuries to tendons, meniscus and cartilage.

The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention.

Concentrating on the Rotator Cuff and Meniscus represents a market opportunity of almost 2,000,000 surgeries per year in the US alone and the current standard of care does not provide an adequate treatment.

The products under development are intended to address a portion of the $5.6 billion sports medicine market growing at 8% annually.

The company has grown its total headcount to 19, including 13 scientists under contract.

It has also obtained approximately $1 million in a non-dilutive Prima Grant, and over $12 million in funding for research and development has been invested in the technology to date.

Dr. Brent Norton, Executive Chairman and CEO, stated: “We are extremely proud of the progress the Ortho RTi team has made towards meeting the rapidly growing unmet medical needs in a global market. I am confident that these recent developments will firmly position us, as we continue to advance our proprietary biopolymer platform."

The company’s shares were distributed as a dividend by Manitex Capital Inc.

The shares are currently trading at $0.75, and with 18.5 million shares outstanding, the company is capitalized at $13.9 million.

For more information please visit the company’s website www.orthorti.com, call 514-782-0951 or
email info@orthorti.com.

Investor and Media Relations is handled by Stephen Kilmer of Kilmer Lucas, who can re reached at 647-872-4849 or by email stephen@kilmerlucas.com.

I’m Samantha Deutscher for Investmentpitch Media